How does long-term gonadotrophin-releasing hormone (GnRH) agonist therapy provided before in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) compare with standard IVF/ICSI alone for women with endometriosis?

Charalampos Siristatidis

doi:10.1002/cca.2912

How does long-term gonadotrophin-releasing hormone (GnRH) agonist therapy provided before in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) compare with standard IVF/ICSI alone for women with endometriosis?

Charalampos Siristatidis

In: Cochrane Clinical Answers · 2020 · doi:10.1002/cca.2912 · W3007018955

article OA: closed CC0

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis 2019

References (1)

Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis via openalex

Source provenance

openalex: last seen: 2026-06-10T17:14:06.276822+00:00

License: CC0 · commercial use OK

[1] Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis 2019